These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20223478)

  • 21. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
    Groothuis JR
    Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B; Mitchell I; Yi H; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2014 Feb; 33(2):e29-33. PubMed ID: 23989104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014).
    Borecka R; Lauterbach R
    Dev Period Med; 2018; 22(4):308-314. PubMed ID: 30636227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.
    Faldella G; Alessandroni R; Aquilano G; Vandini S; Lanari M; Silvestri M; Pistorio A; Rossi GA
    J Chemother; 2010 Feb; 22(1):30-5. PubMed ID: 20227990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.
    Goddard NL; Cooke MC; Gupta RK; Nguyen-Van-Tam JS
    Epidemiol Infect; 2007 Jan; 135(1):159-62. PubMed ID: 16753078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
    J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.
    Lacaze-Masmonteil T; Seidenberg J; Mitchell I; Cossey V; Cihar M; Csader M; Baarsma R; Valido M; Pollack PF; Groothuis JR;
    Drug Saf; 2003; 26(4):283-91. PubMed ID: 12608889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.
    Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML;
    Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
    La Via WV; Notario GF; Yu XQ; Sharma S; Noertersheuser PA; Robbie GJ
    Pulm Pharmacol Ther; 2013 Dec; 26(6):666-71. PubMed ID: 23523663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors and Main Indications for Palivizumab Prophylaxis in a Second Season Population: Results From the German Synagis Registry 2009-2016.
    Simon A; Gehrmann S; Wagenpfeil G; Wagenpfeil S
    Pediatr Infect Dis J; 2018 Oct; 37(10):987-991. PubMed ID: 30020201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
    Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
    Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
    Borecka R; Lauterbach R; Helwich E
    Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.